眼科

• 论著 • 上一篇    下一篇

微导管辅助的小梁切开术治疗原发性先天性青光眼的远期疗效观察

王怀洲1  胡曼2  辛晨1  石砚1  李猛1  王宁利1   

  1. 1首都医科大学附属北京同仁医院 北京同仁眼科中心  北京市眼科研究所  眼科学与视觉科学北京市重点实验室 100005; 2首都医科大学附属北京儿童医院眼科 国家儿童医学中心 100045
  • 收稿日期:2019-12-10 出版日期:2020-01-25 发布日期:2020-02-12
  • 通讯作者: 王怀洲,Email: trhz_wang@163.vip.com
  • 基金资助:
    首都临床特色应用研究与推广(Z161100000516081)

Long term effectiveness of ab externo microcatheter-assisted trabeculotomy for primary congenital glaucoma

Wang Huaizhou1, Hu Man2, Xin Chen1, Shi Yan1, Li Meng1, Wang Ningli1   

  1. 1Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University; Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing 100005, China; 2Department of Ophthalmology, Beijing Children’s Hospital, Capital Medical University, Beijing 100045, China
  • Received:2019-12-10 Online:2020-01-25 Published:2020-02-12
  • Contact: Wang Huaizhou, Email: trhz_wang@163.vip.com
  • Supported by:
    Application Research and Promotion of Capital Clinical Characteristics (Z161100000516081)

摘要: 目标 评估微导管辅助小梁切开术治疗原发性先天性青光眼的远期效果和安全性。设计 回顾性病例系列。研究对象 2014年2月至2016年12月北京同仁眼科中心微导管辅助小梁切开术治疗的原发性先天性青光眼患者65例(86眼),手术时年龄2个月~11岁,平均(3.7±2.8)岁。方法 术后 3、6、9个月以及1、2、3、4、5、6年进行随访。比较术前、术后末次随访时(或手术失败时)眼压及降眼压药物使用数量的变化。术后不使用降眼压药物,且眼压≤21 mmHg 为绝对成功;术后需使用降眼压药物控制眼压≤21 mmHg为条件成功。主要指标  眼压、抗青光眼药物使用数量、术中及术后并发症,远期手术干预。结果 平均随访(46.3±9.9)个月(36~72个月)。35眼为初次手术,51眼具有抗青光眼手术史。术前平均眼压(32.5±6.4)mmHg,平均应用(2.8±0.6)种药物;末次随访平均眼压(15.6±7.9 )mmHg,平均用药(0.4±1.0)种,二者较术前均显著下降(P均<0.001)。术后 1、3、5年累积绝对成功率分别为90.7%、86.0%、68.8%,累积条件成功率分别为90.7%、88.3%、76.9%。随访至术后5年,累积绝对成功率既往无手术史者(94.3%)比有手术史者(60.2%)高(P=0.04)。无严重手术并发症发生。结论 微导管辅助的小梁切开术治疗原发性先天性青光眼长期安全有效。抗青光眼手术史会影响远期手术成功率。(眼科, 2020, 29: 15-19)

关键词:  , 微导管辅助的小梁切开术;原发性先天性青光眼

Abstract:  Objective To evaluate the long-term effectiveness and safety of ab externo microcatheter-assisted trabeculotomy(MAT) for the surgical management of primary congential glaucoma(PCG). Design Retrospective case series. Participants Consecutive 65 patients (85 eyes) with PCG who underwent ab externo MAT between February 2012 and December 2016 by a single surgeon in Beijing Tongren Eye Center. Methods Patients were followed before and 3, 6, 9 months, 1, 2, 3, 4, 5, 6 years after surgery. Intraocular pressure (IOP) and usage of anti-glaucoma medication were compared between before surgery and last visit after surgery. Surgical success was defined as a postoperative IOP of ≤21 mmHg with (qualified success) or without (complete success) the use of anti-glaucoma medication. Main Outcome Measures IOP, number of anti-glaucoma medication, surgical complications, and further glaucoma surgery performed.  Results Mean follow-up time was 46.3±9.9 months (range: 36-72 months). Post-operative IOP and number of glaucoma drops (15.6 ± 7.9 mmHg, 0.4 ± 1.0 medications) was significantly less than the pre-operative values (32.5±6.4 mmHg, 2.8±0.6 medications; all P<0.001). The 1-, 3-, and 5-year cumulative probabilities of complete success was 90.7%, 86.0%, and 68.8%, and those of qualified success was 90.7%, 88.3%, and 76.9%, respectively. Five-year cumulative probabilities of complete success for eyes with previous surgeries (60.2%) was lower than eyes without previous surgeries (94.3%, P=0.04). Conclusion Ab externo MAT has long-term effectiveness and safety in the management of PCG. Previous anti-glaucoma surgery affects the success rate of Ab externo MAT.  (Ophthalmol CHN, 2020, 29: 15-19)

Key words: ab externo microcatheter-assisted trabeculotomy, primary congenital glaucoma